

"1Q23 results in line"

Share price performance



	1M	3M	12M
Absolute (%)	-8.2	-16.7	21.6
Rel KLCI (%)	-8.2	-13.7	32.1

	BUY	HOLD	SELL
Consensus	3	1	-

Source: Bloomberg

Stock Data

Sector	Oil and Gas
Issued shares (m)	643.0
Mkt cap (RMm)/(US\$m)	868.1/190.7
Avg daily vol - 6mth (m)	1.3
52-wk range (RM)	1.06-1.65
Est free float	50.8%
Stock Beta	0.90
Net cash/(debt)	18.9
ROE (2023E)	22.8%
Derivatives	Yes
Shariah Compliant	Yes
FTSE4Good Constituent	Yes
FBM Emas (Top 200)	Top 26-50%
ESG Rank	
ESG Risk Rating	22.7 (-6.7 yoy)

Key Shareholders

Palace Star	21.1%
Sun Lead	6.2%
AmanahRaya Trustee	5.5%

Source: Bloomberg, Affin Hwang, Bursa Malaysia, ESG Risk Rating Powered by Sustainalytics

Tan Jianyuan, FCCA

T (603) 2146 7538

E jianyuan.tan@affingroup.com

Kelington (KGRB MK)

BUY (maintain)

Up/Downside: +34%

Price Target: RM1.80

Previous Target (Rating): RM1.64 (BUY)

Looking at a record profit year with contracts in hand

- Kelington (KGB) reported 1Q23 core net profit of RM16m, an 82% increase yoy. Results are in line with our and consensus estimates
- 1Q23 is off to a strong start. Activities across regions are progressing well with its liquid carbon dioxide plant utilisation maxed out. We expect additional growth once the second plant commences operation in October 2023
- Raise our 12-month target price to RM1.80 after rolling forward our valuation and reaffirm BUY rating. At 13x forward PE, we think valuation is appealing

Busy executing contracts

KGB's profit base has risen over the past three quarters, registering an average RM16m quarterly profit, on the back of aggressive order book growth. Malaysia (+83% yoy), Singapore (+67% yoy) and China (+69% yoy) remain the key revenue drivers underpinned by robust work orders. 1Q23 core net profit rose 82% yoy to RM16m (1Q22: RM9m) on the back of stronger revenue growth. The Ultra High Purity (UHP) segment remained the largest revenue contributor at 60% in 1Q23. The maiden turnkey contract in Sarawak has reached 90% completion and should be handed over by 3Q23. This should help free up resources for more job wins ahead. Overall results are in line with our estimates.

New growth contribution commencing in 2H23

Revenue and core net profit both declined by 26% and 14% qoq due to fewer working days because of the festive season. We expect the strong earnings momentum to sustain with work progress to pick up in the coming quarters backed by its record high RM1.8bn order book. The liquid carbon dioxide (LCO2) plant is operating at full utilization with the second plant targeted to commence by October 2023, driving further industrial gas segment growth. KGB is on track to match 2022 contract replenishment value with RM570m new jobs secured to-date, which represents 31% of last year's total wins.

Maintain BUY

KGB is well positioned to weather the current macro environment slowdown with its order book in hand providing strong earnings visibility until 2024. We raise our target price to RM1.80, after rolling forward our valuation to 2024E, pegged to an unchanged 18x PE multiple. Maintain BUY. Downside risks include delays in semicon clients' expansion plans, execution delays, lower-than-expected gas recovery plant demand and project cost overruns.

Earnings & Valuation Summary

FYE 31 Dec	2021	2022	2023E	2024E	2025E
Revenue (RMm)	517.7	1,269.5	1,146.5	1,158.2	1,197.5
EBITDA (RMm)	48.7	83.6	89.8	95.0	102.2
Pretax profit (RMm)	38.5	73.6	74.6	81.8	89.3
Net profit (RMm)	31.8	55.4	58.6	64.2	70.0
EPS (sen)	5.0	8.6	9.1	10.0	10.9
PER (x)	27.1	15.5	14.7	13.4	12.3
Core net profit (RMm)	34.5	55.4	58.6	64.2	70.0
Core EPS (sen)	5.4	8.6	9.1	10.0	10.9
Core EPS growth (%)	53.6	60.4	5.7	9.6	9.1
Core PER (x)	24.9	15.5	14.7	13.4	12.3
Net DPS (sen)	2.0	2.5	3.5	4.0	4.5
Dividend Yield (%)	1.5	1.9	2.6	3.0	3.4
EV/EBITDA (x)	16.6	10.1	8.2	7.5	6.7

Chg in EPS (%)

Affin/Consensus (%)

Source: Company, Affin Hwang estimates

-
1.0

-
1.0

-
1.0

Fig 1: Results Comparison

FYE 31 Dec (RMm)	1Q22	4Q22	1Q23	QoQ % chg	YoY % chg	Comments
Revenue	173.3	417.4	308.9	(26.0)	78.2	Revenue growth driven by its high order book
Op costs	(159.8)	(387.1)	(283.0)	(26.9)	77.0	
EBITDA	13.5	30.3	26.0	(14.4)	92.2	
<i>EBITDA margin (%)</i>	<i>7.8</i>	<i>7.3</i>	<i>8.4</i>	<i>1.1ppt</i>	<i>0.6ppt</i>	Better operating leverage
Depn and amort	(1.2)	(1.5)	(1.6)	12.2	34.8	
EBIT	12.3	28.9	24.3	(15.8)	98.0	
<i>EBIT margin (%)</i>	<i>7.1</i>	<i>6.9</i>	<i>7.9</i>	<i>1ppt</i>	<i>0.8ppt</i>	
Int expense	(0.6)	(1.7)	(3.3)	88.4	454.2	
EI	(0.6)	(0.9)	0.0	<i>n.m</i>	<i>n.m</i>	
Pretax profit	11.1	26.2	21.0	(19.7)	89.1	
Core pre tax	11.7	27.1	21.0	(22.5)	79.8	
Tax	(2.6)	(6.8)	(4.4)	<i>n.m</i>	69.3	
<i>Tax rate (%)</i>	<i>23.4</i>	<i>26.0</i>	<i>20.9</i>	<i>-5.1ppt</i>	<i>-2.4ppt</i>	
MI	(0.2)	(1.5)	(0.4)	<i>n.m</i>	<i>n.m</i>	
Net profit	8.3	17.8	16.2	(9.2)	95.0	
EPS (sen)	3.3	7.1	6.4	(9.2)	95.0	
Core net profit	8.9	18.8	16.2	(13.7)	82.4	In line with our expectation

Source: Affin Hwang, Company



Important Disclosures and Disclaimer

Equity Rating Structure and Definitions

BUY	Total return is expected to exceed +10% over a 12-month period
HOLD	Total return is expected to be between -5% and +10% over a 12-month period
SELL	Total return is expected to be below -5% over a 12-month period
NOT RATED	Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information only and not as a recommendation

The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months.

OVERWEIGHT	Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months
NEUTRAL	Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months
UNDERWEIGHT	Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) ("the Company") based on sources believed to be reliable and is not to be taken in substitution for the exercise of your judgment. You should obtain independent financial, legal, tax or such other professional advice, when making your independent appraisal, assessment, review and evaluation of the company/entity covered in this report, and the extent of the risk involved in doing so, before investing or participating in any of the securities or investment strategies or transactions discussed in this report. However, such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (expressed or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. Facts, information, estimates, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel and the same are subject to change without notice. Reports issued by the Company, are prepared in accordance with the Company's policies for managing conflicts of interest. Under no circumstances shall the Company, be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or reliance on the information and/or opinion provided or rendered in this report. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company its directors, its employees and their respective associates may have positions or financial interest in the securities mentioned therein. The Company, its directors, its employees and their respective associates may further act as market maker, may have assumed an underwriting commitment, deal with such securities, may also perform or seek to perform investment banking services, advisory and other services relating to the subject company/entity, and may also make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report. The Company, its directors, its employees and their respective associates, may provide, or have provided in the past 12 months investment banking, corporate finance or other services and may receive, or may have received compensation for the services provided from the subject company/entity covered in this report. No part of the research analyst's compensation or benefit was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Employees of the Company may serve as a board member of the subject company/entity covered in this report.

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.

Copyright © 2021 Sustainalytics. All rights reserved.

This report contains information developed by Sustainalytics. Such information and data are proprietary of Sustainalytics and/or its third-party suppliers (Third-Party Data) and are provided for informational purposes only. They do not constitute an endorsement of any product or project, nor an investment advice and are not warranted to be complete, timely, accurate or suitable for a particular purpose. Their use is subject to conditions available at <https://www.sustainalytics.com/legal-disclaimers>.

This report, or any portion thereof may not be reprinted, sold or redistributed without the written consent of the Company.

This report is printed and published by:
Affin Hwang Investment Bank Berhad (14389-U)
A Participating Organisation of Bursa Malaysia Securities Berhad

22nd Floor, Menara Boustead,
69, Jalan Raja Chulan,
50200 Kuala Lumpur, Malaysia.

T : + 603 2142 3700
F : + 603 2146 7630
research@affinhwang.com

www.affinhwang.com

